Patents by Inventor Robert H Keller
Robert H Keller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090124658Abstract: The present invention relates to improved methods and compositions for treating viral infections and other diseases and conditions that induce a cytokine storm. More particularly, the present invention relates to novel compositions comprising quercitin, and an anti-convulsant, such as phenyloin, in combination with multivitamins as an anti-viral composition and methods of use thereof.Type: ApplicationFiled: December 11, 2008Publication date: May 14, 2009Inventor: Robert H. Keller
-
Patent number: 7479498Abstract: The present invention relates to improved methods and compositions for treating viral infections and other diseases and conditions that induce a cytokine storm. More particularly, the present invention relates to novel compositions comprising quercitin, and an anti-convulsant, such as phenytoin, in combination with mulivitamins as an anti-viral composition and methods of use thereof.Type: GrantFiled: February 14, 2006Date of Patent: January 20, 2009Assignee: Phoenix Biosciences, Inc.Inventor: Robert H. Keller
-
Publication number: 20040171636Abstract: A pharmaceutical composition comprising therapeutically effective quantities of calcium channel blockers in combination with quinolines. In preferred embodiments, the invention further comprises quercetin. The components combine and interact in a manner to effectively treat viral infections.Type: ApplicationFiled: December 22, 2003Publication date: September 2, 2004Inventor: Robert H. Keller
-
Patent number: 6734192Abstract: A pharmaceutical composition comprising therapeutically effective quantities of calcium channel blockers in combination with quinolines. In preferred embodiments, the invention further comprises quercetin. The components combine and interact in a manner to effectively treat viral infections.Type: GrantFiled: August 23, 2000Date of Patent: May 11, 2004Assignee: MP-1 Inc.Inventor: Robert H. Keller
-
Patent number: 6432455Abstract: The composition disclosed is a unique formulation of Traditional Chinese-Medicine (TCM) extracts created to reduce the debilitating symptoms of allergies. It combines a number of organically grown, but, non-organically extracted, standardized formulations of natural ingredients which have been used singly for hundreds of years for symptomatic relief of allergies. These include Ginseng and Gan Cao, which provide a natural anti-inflammatory effect; Bai Gao, which prevent the smooth muscle spasms associated with allergic reactions; Suan Zao ren, which provides an antihistamine effect without the usual sedative effect; and Wu Mai, which reduces the local swelling associated with allergies. Combined, it was unexpectedly found that these ingredients provide a natural, non-drying, non-sedating alternative to antihistamines, without inhibiting the natural healing mechanisms.Type: GrantFiled: November 30, 2000Date of Patent: August 13, 2002Assignee: Vit Immune, L.L.C.Inventors: Robert H Keller, Xue-Lan Wen
-
Patent number: 6262019Abstract: Glutathione (GSH) is a tripeptide of extreme importance as a catalyst, reductan, and reactant. It can be depleted intracellulary either by forming a direct complex with an electrophilic agent (accomplished investigationally by agents such as bromobenzene or diethyl maleate), by way of inhibition of synthesis, or by subjecting cells to oxidant stress. Most cells, except for epithelia cells, do not have a direct transport capacity for intact GSH. Non-epithelial cells must either transport precursor substrates for GSH synthesis or salvage amino acids from circulating GSH for reuse in intracellular resynthesis. Dietary cysteine is a rate limiting substrate for the synthesis of glutathione and also inhibits GSH efflux. Although GSH is synthesized from precursors in virtually all cells, the liver is the main source of plasma GSH. Protection and support of liver function is paramount to elevating GSH levels.Type: GrantFiled: April 29, 1999Date of Patent: July 17, 2001Assignee: Vit-Immune, L. C.Inventors: Robert H Keller, David W Kirshenbaum
-
Publication number: 20010000144Abstract: The composition disclosed is a unique formulation of Traditional Chinese Medicine (TCM) extracts created to reduce the debilitating symptoms of allergies. It combines a number of organically grown, but, non-organically extracted, standardized formulations of natural ingredients which have been used singly for hundreds of years for symptomatic relief of allergies. These include Ginseng and Gan Cao, which provide a natural anti-inflammatory effect; Bai Gao, which prevent the smooth muscle spasms associated with allergic reactions; Suan Zao ren, which provides an antihistamine effect without the usual sedative effect; and Wu Mai, which reduces the local swelling associated with allergies. Combined, it was unexpectedly found that these ingredients provide a natural, non-drying, non-sedating alternative to antihistamines, without inhibiting the natural healing mechanisms.Type: ApplicationFiled: November 30, 2000Publication date: April 5, 2001Inventors: Robert H. Keller, Xue-Lan Wen
-
Patent number: 6180106Abstract: The composition disclosed is a unique formulation of Traditional Chinese Medicine (TCM) extracts created to reduce the debilitating symptoms of allergies. It combines a number of organically grown, but, non-organically extracted, standardized formulations of natural ingredients which have been used singly for hundreds of years for symptomatic relief of allergies. These include Ginseng and Gan Cao, which provide a natural anti-inflammatory effect; Bai Gao, which prevent the smooth muscle spasms associated with allergic reactions; Suan Zao ren, which provides an antihistamine effect without the usual sedative effect; and Wu Mai, which reduces the local swelling associated with allergies. Combined, it was unexpectedly found that these ingredients provide a natural, non-drying, non-sedating alternative to antihistamines, without inhibiting the natural healing mechanisms.Type: GrantFiled: July 8, 1999Date of Patent: January 30, 2001Assignee: Vit-Immune, L.C.Inventors: Robert H Keller, Xue-Lan Wen
-
Patent number: RE39705Abstract: Glutathione (GSH) is a tripeptide of extreme importance as a catalyst, reductan, and reactant. It can be depleted intra-cellularly either by forming a direct complex with an electrophilic agent (accomplished investigationally by agents such as bromobenzene or diethyl maleate), by way of inhibition of synthesis, or by subjecting cells to oxidant stress. Most cells, except for epithelia cells, do not have a direct transport capacity for intact GSH. Non-epithelial cells must either transport precursor substrates for GSH synthesis or salvage amino acids from circulating GSH for reuse in intracellular resynthesis. Dietary cysteine is a rate limiting substrate for the synthesis of glutathione and also inhibits GSH efflux. Although GSH is synthesized from precursors in virtually all cells, the liver is the main source of plasma GSH. Protection and support of liver function is paramount to elevating GSH levels.Type: GrantFiled: November 26, 2001Date of Patent: June 26, 2007Assignee: Vit-Immune, L.C.Inventors: Robert H. Keller, David Kirchenbaum
-
Patent number: RE40849Abstract: Glutathione (GSH) is a tripeptide of extreme importance as a catalyst, reductan, and reactant. It can be depleted intracellulary either by forming a direct complex with an electrophilic agent (accomplished investigationally by agents such as bromobenzene or diethyl maleate), by way of inhibition of synthesis, or by subjecting cells to oxidant stress. Most cells, except for epithelia cells, do not have a direct transport capacity for intact GSH. Non-epithelial cells must either transport precursor substrates for GSH synthesis or salvage amino acids from circulating GSH for reuse in intracellular resynthesis. Dietary cysteine is a rate limiting substrate for the synthesis of glutathione and also inhibits GSH efflux. Although GSH is synthesized from precursors in virtually all cells, the liver is the main source of plasma GSH. Protection and support of liver function is paramount to elevating GSH levels.Type: GrantFiled: January 9, 2007Date of Patent: July 14, 2009Assignee: Vit Immune, L.C.Inventors: Robert H. Keller, David W. Kirchenbaum